Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 71 of 95, showing 5 Applications out of 474 total, starting on record 351, ending on 355

# Protocol No Study Title Investigator(s) & Site(s)

351.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View

352.

ECCT/21/11/05   SOLIDARITY TRIAL PLUS
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. loice Ombajo
Site(s) in Kenya
1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county)
2. The Nairobi Hospital (Nairobi City county)
 
View

353.

ECCT/20/04/01   Solidarity
    An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kilifi Kemri-Wellcome (Kilifi county)
2. Kenya National Hospital (Nairobi City county)
3. Coast PGH (Mombasa county)
4. The Nairobi Hospital (Nairobi City county)
5. Aga Khan University Hospital (Nairobi City county)
6. Moi Teahing and Referal Hospital (Uasin Gishu county)
7. Kenyatta University teaching research and referal hospital (Kiambu county)
 
View

354.

ECCT/14/09/01   Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa
    An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa.   Study number: MALARIA-076 (200599)   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project
 
View

355.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
View